Amgen Inc. (ISIN US0311621009) stock sits in the large-cap pharma bracket with investors closely watching how recent double-digit revenue growth and the integration of Horizon Therapeutics translate into future earnings power. In 2023 Amgen reported revenue of roughly $28.2 billion, up around 7% from about $26.3 billion in 2022, while the company continued to return substantial cash to shareholders through dividends and buybacks. For many portfolio managers, the key question is how quickly the obesity and oncology pipeline can offset patent erosion in mature products and support long-term growth.
Revenue up around 7 percent
In its 2023 fiscal year Amgen generated approximately $28.2 billion in total revenue compared with about $26.3 billion in 2022, implying growth of around 7%. This expansion was driven by a combination of volume growth in newer products and the incremental contribution from the Horizon Therapeutics acquisition, which brought Tepezza, Krystexxa and other rare-disease assets into Amgen’s portfolio. Even with pricing pressure in several legacy franchises, Amgen managed to expand its top line in the mid?single?digit range, which places it roughly in line with many other large-cap biopharma peers.
On the profitability side, Amgen reported 2023 GAAP net income in the neighborhood of $6.8 billion compared with about $6.6 billion a year earlier, indicating modest earnings growth despite acquisition-related costs. Adjusted earnings per share for 2023 came in around $18.65, slightly above the roughly $17.69 reported for 2022, an increase of about 5%. The combination of mid?single?digit revenue growth and mid?single?digit EPS growth underscores that Amgen has maintained cost discipline while absorbing integration expenses and investing in late?stage research.
Obesity and oncology pipeline under scrutiny
For investors, the strategic focus has shifted toward Amgen’s emerging obesity and oncology candidates as potential engines of higher growth over the coming years. One of the most closely watched assets is AMG 133, later named maridebart cafraglutide, which targets the GLP?1 pathway and is being developed for obesity and related metabolic indications. Early?stage clinical data suggested meaningful weight?loss effects, positioning the program as a potential competitor in the fast?growing obesity market that has been dominated by GLP?1 drugs from rivals.
In oncology, Amgen’s KRAS G12C inhibitor Lumakras (sotorasib) has become a reference product in its niche, though the market remains competitive and subject to evolving treatment standards. Amgen has also been developing bispecific T?cell engagers and other targeted therapies in hematology and solid tumors, aiming to sustain oncology revenue as older products such as Neulasta and Epogen face biosimilar and generic competition. The company is using its increased scale following the Horizon transaction to spread R&D costs across a broader revenue base, which may support margins over time if late?stage programs read out positively.
Read deeper
More background on Amgen
Additional articles and official filings provide more detail on Amgen’s quarterly results, pipeline updates and the integration of recent acquisitions
All news on AmgenInvestor Relations
Key products support multi-billion revenue base
Amgen’s current commercial portfolio is anchored by several blockbuster medicines that together deliver a substantial share of its more than $28 billion in annual sales. The osteoporosis drug Prolia has been one of the standout performers, with recent annual sales running in the multi?billion?dollar range and benefiting from demographic trends in aging populations. The oncology agent Kyprolis, used in multiple myeloma, also contributes significant revenue, providing diversification within hematology.
In cardiovascular disease, Repatha, a PCSK9 inhibitor for lowering LDL cholesterol, has gradually gained traction after earlier pricing challenges. Meanwhile, biosimilar products add an additional revenue stream, leveraging Amgen’s experience in biologics manufacturing to compete as patents expire across the industry. The integration of Horizon’s rare?disease therapies has further diversified the portfolio toward immunology and ophthalmology, which may help smooth revenue volatility as individual products move through their life cycles.
Amgen stock in the large-cap pharma landscape
Amgen stock represents exposure to a diversified large-cap biopharmaceutical company with a mix of mature cash-generating franchises and higher?risk, higher?reward innovative programs. The company has historically maintained an active capital?return policy, combining a regular dividend with share repurchases. In recent years the dividend has been increased at a mid?single?digit annual pace, and Amgen has allocated several billion dollars per year to buybacks when valuation and balance?sheet conditions allowed.
Valuation for Amgen stock tends to be compared with peers in the S&P 500 healthcare sector, where investors evaluate metrics such as price?to?earnings ratios, free?cash?flow yields and dividend yields against the backdrop of patent exposure and pipeline momentum. The integration of Horizon adds both revenue and complexity, as regulators and payers scrutinize pricing in rare diseases while Amgen seeks to extract cost synergies and scale benefits. For long?term holders, the interplay between steady cash flows from established therapies and the outcome of obesity and oncology programs will likely remain the dominant drivers of sentiment around Amgen stock.
Representative product: Prolia
Among Amgen’s key products, Prolia stands out as a representative example of how a single medicine can shape the financial profile of a large-cap biotech. The drug, indicated for osteoporosis in postmenopausal women and other high?risk groups, has generated multi?billion?dollar annual sales in recent years and benefits from a growing patient pool. Its performance illustrates how chronic?use biologics can provide recurring revenue that supports ongoing research spending and shareholder returns
Amgen stock and market perception
Amgen stock is listed on Nasdaq under the ticker AMGN and is widely held by institutional and retail investors seeking exposure to the biopharmaceutical sector. Market participants typically assess the shares in the context of factors such as revenue growth from the roughly $28.2 billion base reported for 2023, the trajectory of adjusted EPS from about $17.69 in 2022 to around $18.65 in 2023, and the sustainability of cash flows needed to fund both R&D and dividends. As sentiment toward obesity treatments, oncology innovations and rare?disease pricing evolves, these discussions are likely to influence how Amgen stock trades relative to the broader market.
Amgen stock at a glance
- Company: Amgen Inc.
- ISIN: US0311621009
- Ticker: NASDAQ: AMGN
- Trading venue: Nasdaq
- Sector / Industry: Health Care / Biotechnology
- Index membership: S&P 500
Discuss Amgen stock on social media
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI
en | US0311621009 | AMGEN INC. | boerse | 69816050 | bgmi
